Fairvalue-Calculator Fairvalue-Calculator
EN DE

Nkarta, Inc (NKTX) Fair Value & Analysis

Healthcare · US · Market cap $205M

Price$2.89
Fair Value$2.66
Upside-8.0%
Quality95/100
Evidence: Low Range $1.76 – $3.33

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Nkarta, Inc (NKTX) currently trades at $2.89, while our model-based Fair Value estimate is $2.66 — implying the stock looks roughly 8.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Nkarta, Inc (NKTX) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $2.66 versus a price of $2.89 — about −8% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NKTX?
Our 21-model fair value for Nkarta, Inc is $2.66 (as of Jun 25, 2026), built from audited fundamentals. The current price is $2.89.
What is the quality score of NKTX?
Nkarta, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.